LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Avatud

SektorTervishoid

44.38 1.16

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

44.19

Max

44.93

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+32.2% upside

Turustatistika
By TradingEconomics
Turukapital	19M 3.2B
Eelmine avamishind	43.22
Eelmine sulgemishind	44.38

Uudiste sentiment

By Acuity

34%

66%

97 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. nov 2025, 17:44 UTC

Tulu

Suurimad hinnamuutused turgudel

Deere Warns of Tough Year Ahead as Earnings, Sales Fall -- Update

27. nov 2025, 00:00 UTC

Market Talk

Rio Tinto's Coming Investor Briefing Seen Focused on Costs, Lithium, Asset Sales -- Market Talk

26. nov 2025, 23:47 UTC

Market Talk

Nikkei May Rise as Fears About Potential AI Bubble Ease -- Market Talk

26. nov 2025, 23:28 UTC

Market Talk

Mortgage Refinancing in New Zealand Will Spur Recovery -- Market Talk

26. nov 2025, 23:21 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26. nov 2025, 23:21 UTC

Market Talk

RBNZ Rate Cuts Finally Getting Traction With Consumers -- Market Talk

26. nov 2025, 23:02 UTC

Market Talk

Steelmaking Coal Price Signal Knocked by China Import Shift -- Market Talk

26. nov 2025, 21:38 UTC

Tulu

These Stocks Moved the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26. nov 2025, 21:25 UTC

Tulu

Li Auto Posts Surprise Loss, Stock Rises. What's Next for Its Diving EV Sales. -- Barrons.com

26. nov 2025, 21:17 UTC

Omandamised, ülevõtmised, äriostud

Commercial Metals Co Announces Closing of $2B Senior Notes Offering

26. nov 2025, 21:16 UTC

Tulu

Deere Beat Earnings Estimates. Why the Stock Is Falling. -- Barrons.com

26. nov 2025, 21:09 UTC

Tulu

Roblox Isn't Playing Games. Why the Stock Could -2-

26. nov 2025, 21:09 UTC

Tulu

Roblox Isn't Playing Games. Why the Stock Could Jump 50%. -- Barrons.com

26. nov 2025, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Charter Communications Stock Is a Disaster. The Answer Could Be a 10% Dividend. -- Barrons.com

26. nov 2025, 20:25 UTC

Omandamised, ülevõtmised, äriostud

Charter Communications Stock Is a Disaster. The Answer Could Be a 10% Dividend. -- Barrons.com

26. nov 2025, 20:15 UTC

Tulu

These Stocks Are Moving the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26. nov 2025, 20:08 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

26. nov 2025, 20:06 UTC

Market Talk

U.S. Natural Gas Settles Higher Ahead of Holiday -- Market Talk

26. nov 2025, 19:30 UTC

Tulu

These Stocks Are Moving the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26. nov 2025, 19:21 UTC

Omandamised, ülevõtmised, äriostud

Teck Resources: ISS and Glass Lewis Recommend Teck Hldrs Vote for Anglo American Deal

26. nov 2025, 18:43 UTC

Market Talk

U.S. Natural Gas Storage Down for Second Straight Week -- Market Talk

26. nov 2025, 18:41 UTC

Market Talk

U.S. Oil Rig Count Falls By 12 to 407 -- Market Talk

26. nov 2025, 18:19 UTC

Tulu

Workday Beat Earnings Estimates. The Stock Is Down 10% Anyway. -- Barrons.com

26. nov 2025, 17:51 UTC

Tulu

Deere Forecasts Higher Tariff Costs, Less Profit in 2026 -- WSJ

26. nov 2025, 17:50 UTC

Tulu

These Stocks Are Moving the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26. nov 2025, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Energy & Utilities Roundup: Market Talk

26. nov 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26. nov 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

26. nov 2025, 17:16 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Blue Owl Is Having a Rough Year. Its Co-CEO Says -2-

26. nov 2025, 17:16 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Blue Owl Is Having a Rough Year. Its Co-CEO Says Investors' Fears Are 'Ungrounded.' -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

32.2% tõus

12 kuu keskmine prognoos

Keskmine 55.59 USD 32.2%

Kõrge 65 USD

Madal 44 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

97 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.